文献速递心脑血管急症

氯噻酮与氢氯噻嗪治疗高血压的心血管事件比较

Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
PubMed 文献 · N Engl J Med · 2022-12-14
一句话结论在65岁以上接受25或50 mg/d氢氯噻嗪的高血压患者中,换用氯噻酮12.5或25 mg/d未降低主要心血管事件或非癌死亡。

该务实试验纳入13,523例65岁以上、来自退伍军人事务部医疗系统、正在服用氢氯噻嗪25或50 mg/d的高血压患者,随机继续氢氯噻嗪或换用氯噻酮12.5或25 mg/d。中位随访2.4年,主要复合终点(非致死性心肌梗死、卒中、心力衰竭住院、不稳定型心绞痛紧急冠脉血运重建、非癌死亡)在氯噻酮组702例(10.4%)与氢氯噻嗪组675例(10.0%)间差异很小(HR 1.04;95%CI 0.94–1.16;P=0.45)。主要终点的各组分均无组间差异;氯噻酮组低钾血症发生率高于氢氯噻嗪组(6.0% vs 4.4%,P<0.001)。作者结论认为,在临床常用剂量的噻嗪类利尿剂中,氯噻酮并未比氢氯噻嗪降低主要心血管事件或非癌死亡。

要点

  • 65岁以上正在服用氢氯噻嗪25或50 mg/d的高血压患者,换用氯噻酮12.5或25 mg/d未降低主要心血管事件(HR 1.04;95%CI 0.94–1.16;P=0.45)。
  • 主要复合终点发生率为氯噻酮组10.4%(702例)vs 氢氯噻嗪组10.0%(675例),中位随访2.4年。
  • 主要终点的各组分(非致死性心肌梗死、卒中、心力衰竭住院、不稳定型心绞痛紧急冠脉血运重建、非癌死亡)均无组间差异。
  • 氯噻酮组低钾血症发生率高于氢氯噻嗪组(6.0% vs 4.4%,P<0.001)。
  • 基线时94.5%(12,781例)患者使用氢氯噻嗪25 mg/d,两组平均基线收缩压均为139 mm Hg。

适用人群与场景

  • 65岁及以上、退伍军人事务部医疗系统内、正在服用氢氯噻嗪25或50 mg/d的高血压成人。

处置流程与药物剂量

  • 随机继续氢氯噻嗪或换用氯噻酮,氯噻酮剂量为12.5或25 mg/d。

研究设计与关键结果

  • 务实试验随机13,523例患者,平均年龄72岁;基线时12,781例(94.5%)使用氢氯噻嗪25 mg/d,两组平均基线收缩压均为139 mm Hg。
  • 中位随访2.4年,主要复合终点(非致死性心肌梗死、卒中、心力衰竭住院、不稳定型心绞痛紧急冠脉血运重建、非癌死亡)在氯噻酮组702例(10.4%)与氢氯噻嗪组675例(10.0%)间差异很小(HR 1.04;95%CI 0.94–1.16;P=0.45)。
  • 主要终点的各组分均无组间差异。
  • 低钾血症发生率氯噻酮组6.0% vs 氢氯噻嗪组4.4%(P<0.001)。

证据类型、等级与局限

  • 证据类型:务实随机对照试验(由退伍军人事务部合作研究计划资助;ClinicalTrials.gov编号NCT02185417)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在临床常用剂量的噻嗪类利尿剂中,接受氯噻酮的患者主要心血管事件或非癌死亡发生率并未低于接受氢氯噻嗪的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear.

METHODS: In a pragmatic trial, we randomly assigned adults 65 years of age or older who were patients in the Department of Veterans Affairs health system and had been receiving hydrochlorothiazide at a daily dose of 25 or 50 mg to continue therapy with hydrochlorothiazide or to switch to chlorthalidone at a daily dose of 12.5 or 25 mg. The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and non-cancer-related death. Safety was also assessed.

RESULTS: A total of 13,523 patients underwent randomization. The mean age was 72 years. At baseline, hydrochlorothiazide at a dose of 25 mg per day had been prescribed in 12,781 patients (94.5%). The mean baseline systolic blood pressure in each group was 139 mm Hg. At a median follow-up of 2.4 years, there was little difference in the occurrence of primary-outcome events between the chlorthalidone group (702 patients [10.4%]) and the hydrochlorothiazide group (675 patients [10.0%]) (hazard ratio, 1.04; 95% confidence interval, 0.94 to 1.16; P = 0.45). There were no between-group differences in the occurrence of any of the components of the primary outcome. The incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%, P<0.001).

CONCLUSIONS: In this large pragmatic trial of thiazide diuretics at doses commonly used in clinical practice, patients who received chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients who received hydrochlorothiazide. (Funded by the Veterans Affairs Cooperative Studies Program; ClinicalTrials.gov number, NCT02185417.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022. PMID: 36516076. doi:10.1056/NEJMoa2212270

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。